Article
Immunology
Carl R. R. Alving, Mangala Rao, Gary R. R. Matyas
Summary: AS01 and ALFQ are two vaccine adjuvants composed of liposomes containing a mixture of natural substances. AS01 has been successfully used in malaria and shingles vaccines, while ALFQ is a similar adjuvant. We compared their chemical structures and physical characteristics and hypothesized that some side effects observed after liposome-based vaccine injections might be caused by the release of free fatty acids and lysophospholipids.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Tetsuya Saito, Yukiya Sako, Fumi Sato-Kaneko, Tadashi Hosoya, Shiyin Yao, Fitzgerald S. Lao, Jonathan Shpigelman, Karen Messer, Minya Pu, Nikunj M. Shukla, Michael Chan, Paul J. Chu, Howard B. Cottam, Tomoko Hayashi, Dennis A. Carson, Maripat Corr
Summary: A potential adjuvant molecule (2D216) was found to enhance TLR4 agonist-mediated immune responses in vitro. In murine vaccination studies, the combination of 2D216 with MPLA acted as a potent co-adjuvant, increasing antigen-specific IgG levels and protecting against lethal influenza virus challenge. The co-adjuvant MPLA/2D216 produced Th1 dominant immune responses and showed excellent safety with minimal local reactogenicity and no systemic inflammatory response.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Cell Biology
M. Gordon Joyce, Hannah A. D. King, Ines Elakhal-Naouar, Aslaa Ahmed, Kristina K. Peachman, Camila Macedo Cincotta, Caroline Subra, Rita E. Chen, Paul Thomas, Wei-Hung Chen, Rajeshwer S. Sankhala, Agnes Hajduczki, Elizabeth J. Martinez, Caroline E. Peterson, William C. Chang, Misook Choe, Clayton Smith, Parker J. Lee, Jarrett A. Headley, Mekdi G. Taddese, Hanne A. Elyard, Anthony Cook, Alexander Anderson, Kathryn McGuckin Wuertz, Ming Dong, Isabella Swafford, James Brett Case, Jeffrey R. Currier, Kerri G. Lal, Sebastian Molnar, Manoj S. Nair, Vincent Dussupt, Sharon P. Daye, Xiankun Zeng, Erica K. Barkei, Hilary M. Staples, Kendra Alfson, Ricardo Carrion, Shelly J. Krebs, Dominic Paquin-Proulx, Nicos Karasavva, Victoria R. Polonis, Linda L. Jagodzinski, Mihret F. Amare, Sandhya Vasan, Paul T. Scott, Yaoxing Huang, David D. Ho, Natalia de Val, Michael S. Diamond, Mark G. Lewis, Mangala Rao, Gary R. Matyas, Gregory D. Gromowski, Sheila A. Peel, Nelson L. Michael, Diane L. Bolton, Kayvon Modjarrad
Summary: This study developed an adjuvanted SARS-CoV-2 vaccine, which was found to induce strong immune responses and effectively eliminate the virus when challenged with high doses in nonhuman primates.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Agnieszka Sulima, Fuying Li, Jeffrey Brian Morgan, Phong Truong, Joshua F. G. Antoline, Therese Oertel, Rodell C. Barrientos, Oscar B. Torres, Zoltan Beck, Gregory H. Imler, Jeffrey R. Deschamps, Gary R. Matyas, Arthur E. Jacobson, Kenner C. Rice
Summary: This study focuses on the design and synthesis of haptens for anti-heroin vaccines, evaluating their efficacy in inducing protective antibodies against heroin in vivo. The results show that haptens with a linker at the C1 position can induce protective effects, with significant differences in antibody specificity among different haptens.
Article
Immunology
Jiao Tong, Chenxi Zhu, Hanyu Lai, Chunchao Feng, Dapeng Zhou
Summary: The study investigated the efficacy of a recombinant trimeric Spike protein as a potential COVID-19 vaccine candidate, showing it induced Spike protein-specific antibodies with high titers and neutralizing capabilities. The identified immunodominant receptor-binding domain (RBD) and linear epitopes in different regions contribute to its potential effectiveness against the virus.
Article
Biotechnology & Applied Microbiology
Debra Wu, Zongmin Zhao, Jayoung Kim, Amaya Razmi, Lily Li-Wen Wang, Neha Kapate, Yongsheng Gao, Kevin Peng, Anvay Ukidve, Samir Mitragotri
Summary: Cancer therapy is increasingly focusing on targeting the tumor immune microenvironment, with chemotherapy inducing immunostimulatory responses that can be enhanced by immune-modulating agents. However, long-term immune responses may be lacking in some cases, despite initial efficacy against tumors.
BIOENGINEERING & TRANSLATIONAL MEDICINE
(2021)
Article
Biology
Danniele L. Vale, Camila S. Freitas, Vivian T. Martins, Gabriel J. L. Moreira, Amanda S. Machado, Fernanda F. Ramos, Isabela A. G. Pereira, Raquel S. Bandeira, Marcelo M. de Jesus, Grasiele S. V. Tavares, Fernanda Ludolf, Miguel A. Chavez-Fumagalli, Alexsandro S. Galdino, Ricardo T. Fujiwara, Lilian L. Bueno, Bruno M. Roatt, Myron Christodoulides, Eduardo A. F. Coelho, Daniela P. Lage
Summary: Our study used an immunotherapeutic approach combining a vaccine and drug to successfully treat mice infected with Leishmania parasites. This approach significantly reduced the parasite load in the animals' internal organs and increased the production of protective antibodies. The inclusion of the vaccine and adjuvant also reduced the toxicity of the drug.
Article
Oncology
Seyyedeh Maryam Afshani, Reihaneh Mirhassani, Hamed Hosseini, Reihaneh Hosseini, Afsaneh Tehranian, Reza Malekzadeh, Afshin Ostovar, Amir Hossein Abdolghaffari, Mohammad Amin Ghobadi, Behnaz Hedayatjoo, Delara Hazegh Fetratjoo, Zahra Rezagholi, AmirHossein Anari, Ashraf Moini
Summary: This study compared the immunogenicity and safety of Papilloguard and Cervarix vaccines, finding that both vaccines were effective in inducing an immune response with similar rates of seroconversion and tolerable adverse events.
EUROPEAN JOURNAL OF CANCER PREVENTION
(2022)
Article
Immunology
Fernando Augusto Siqueira Mathias, Thais Lopes Valentim Di Paschoale Ostolin, Levi Eduardo Soares Reis, Jamille Mirelle de Oliveira Cardoso, Rory Cristiane Fortes De Brito, Rodrigo Dian de Oliveira Aguiar Soares, Bruno Mendes Roatt, Paula Melo de Abreu Vieira, Alexandre Barbosa Reis
Summary: This study evaluated the effect and optimal dose of adjuvant systems for a vaccine candidate against Leishmania (Viannia) braziliensis. The combination of saponin and monophosphoryl lipid A (SM) as an adjuvant system increased the production of TNF and IFN-gamma, leading to the generation of central and effector memory CD4(+) T cells. Therefore, using an adjuvant system can enhance the innate immune response and has the potential for future vaccine development.
Review
Immunology
Bharathi Karunakaran, Raghav Gupta, Pranav Patel, Sagar Salave, Amit Sharma, Dhruv Desai, Derajram Benival, Nagavendra Kommineni
Summary: Lipid-based vaccine delivery systems have attracted significant interest due to their ability to protect antigens from enzymatic degradation by encapsulating them in vesicles. The particulate form of lipid-based nanocarriers stimulates immune responses, making them ideal antigen carriers. These nanocarriers can be tailored to achieve desired characteristics through lipid composition modification and appropriate preparation methods, enhancing their effectiveness as vaccine delivery carriers.
Article
Engineering, Biomedical
Bon Il Koo, Seon-Mi Jin, Hayeon Kim, Dong Jae Lee, Eunji Lee, Yoon Sung Nam
Summary: The study introduced robust conjugation-free multilamellar protein antigen-lipid hybrid nanovesicles (MPLVs) for efficient antigen-specific immune responses, increasing immunological surface markers and cytokines in dendritic cells. Vaccination with MPLVs significantly enhanced anti-antigen antibody and interferon-gamma production by activating CD4(+) and CD8(+) T cells, suggesting MPLVs as a promising nanovaccine delivery platform for efficient antigen cross-presentation.
ADVANCED HEALTHCARE MATERIALS
(2021)
Article
Immunology
Chau Thuy Tien Le, So Yeon Ahn, Sang-Moo Kang, Eun-Ju Ko
Summary: The combination adjuvant of MPL and poly I:C was found to promote recruitment, differentiation, and activation of NK cells, as well as reciprocal activation with DCs, suggesting a promising vaccine candidate for enhancing cellular immune responses.
Article
Multidisciplinary Sciences
Xiuran Wang, Peng Li, Amit K. Singh, Xiangmin Zhang, Ziqiang Guan, Roy Curtiss, Wei Sun
Summary: A recombinant enteric Yersinia pseudotuberculosis PB1(+) strain was designed to synthesize an adjuvant form of lipid A and a high synthesis of the Yersinia pestis LcrV antigen. The recombinant strain increased the production of outer membrane vesicles enclosing high amounts of LcrV. Immunization with the vesicles provided complete protection against Y. pestis infection and induced robust immune responses.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Article
Chemistry, Multidisciplinary
Saugata Majumder, Shreya Das, Peng Li, Nicole Yang, Hazel Dellario, Haixin Sui, Ziqiang Guan, Wei Sun
Summary: This study demonstrates the feasibility of a newly constructed Yersinia pseudotuberculosis mutant as a potential vaccine candidate against plague, which provides complete protection and reduces reactogenicity.
Article
Medicine, Research & Experimental
Olivia Amanda Oest Mullertz, Peter Andersen, Dennis Christensen, Camilla Foged, Aneesh Thakur
Summary: The mucosal surfaces of the lungs are a major site for entry of airborne pathogens and pulmonary vaccination can induce protective mucosal immunity. Researchers found that altering the surface charge of liposomes can enhance specific T-cell responses, but the impact on mucosal immunity remains unclear.
MOLECULAR PHARMACEUTICS
(2022)
Article
Immunology
Oscar B. Torres, Gary R. Matyas, Mangala Rao, Kristina K. Peachman, Rashmi Jalah, Zoltan Beck, Nelson L. Michael, Kenner C. Rice, Arthur E. Jacobson, Carl R. Alving
Article
Medicine, Research & Experimental
Rodell C. Barrientos, Eric W. Bow, Connor Whalen, Oscar B. Torres, Agnieszka Sulima, Zoltan Beck, Arthur E. Jacobson, Kenner C. Rice, Gary R. Matyas
MOLECULAR PHARMACEUTICS
(2020)
Article
Biotechnology & Applied Microbiology
Christopher P. Karch, Peter Burkhard, Gary R. Matyas, Zoltan Beck
Summary: Developing an efficacious HIV-1 vaccine has been challenging due to the virus's diversity. Various approaches, such as sequence optimization and the use of protein nanoparticles, may need to be combined to overcome this obstacle.
Article
Immunology
Cosette G. Schneider, Justin A. Taylor, Michael Q. Sibilo, Kazutoyo Miura, Katherine L. Mallory, Christopher Mann, Christopher Karch, Zoltan Beck, Gary R. Matyas, Carole A. Long, Elke Bergmann-Leitner, Peter Burkhard, Evelina Angov
Summary: This study investigates the folding and immunogenicity of heterogeneous antigen display, demonstrating that antigen orientation and folding impact the elicited immune response. When appropriately designed, SAPN can serve as an adaptable platform for effective multi-antigen display.
Article
Biochemical Research Methods
Rodell C. Barrientos, Connor Whalen, Oscar B. Torres, Agnieszka Sulima, Eric W. Bow, Essie Komla, Zoltan Beck, Arthur E. Jacobson, Kenner C. Rice, Gary R. Matyas
Summary: By combining heroin and fentanyl haptens in a bivalent vaccine adjuvanted with liposomes, high IgG titers were produced in mice, protecting them from the effects of heroin and fentanyl. The vaccine showed no cross-reactivity to other opioids in vivo, indicating its potential efficacy and worth further investigation.
BIOCONJUGATE CHEMISTRY
(2021)
Article
Immunology
Christopher P. Karch, Gary R. Matyas
Summary: Efforts to find an efficacious vaccine for HIV-1 have faced numerous challenges, with the use of nanotechnology and nanoparticles showing promise in developing immunogens. Nanovaccines have the potential to significantly impact the field of HIV-1 vaccine development by improving immunogenicity and presentation of antigens. Further research is necessary to fully understand the role of nanovaccines in creating a successful HIV-1 vaccine.
EXPERT REVIEW OF VACCINES
(2021)
Article
Immunology
Clara J. Sei, Mangala Rao, Richard F. Schuman, Luke T. Daum, Gary R. Matyas, Nimisha Rikhi, Kevin Muema, Alexander Anderson, Ousman Jobe, Kellie A. Kroscher, Carl R. Alving, Gerald W. Fischer
Summary: The development of multi-epitope unconjugated influenza composite peptides formulated with ALFQ has shown broad immunogenicity in inducing early and broad antibody responses in mice, providing a novel strategy for the development of a universal influenza vaccine.
Article
Immunology
Essie Komla, Oscar B. Torres, Rashmi Jalah, Agnieszka Sulima, Zoltan Beck, Carl R. Alving, Arthur E. Jacobson, Kenner C. Rice, Gary R. Matyas
Summary: Opioid use disorder is a serious health issue that has been increasing significantly in the past decade. Developing a conjugate vaccine to generate high affinity antibodies and neutralize opioids before they reach the brain is a complementary strategy to combat the crisis. The vaccine components include an opioid hapten conjugated to a carrier protein with adjuvants, and preexisting immunity to the carrier protein does not affect the immunogenicity and efficacy of the vaccine.
Article
Immunology
Mark D. Langowski, Farhat A. Khan, Sofya Savransky, Dallas R. Brown, Arasu Balasubramaniyam, William B. Harrison, Xiaoyan Zou, Zoltan Beck, Gary R. Matyas, Jason A. Regules, Robin Miller, Lorraine A. Soisson, Adrian H. Batchelor, Sheetij Dutta
Summary: The efficacy of the malaria vaccine RTS,S is low and short-lived, and mapping inhibitory monoclonal antibodies may improve CSP vaccines. The combination of junctional and NPNA epitopes reduces immunogenicity and efficacy. Tobacco Mosaic Virus (TMV) is a versatile vaccine platform for displaying epitopes.
Article
Immunology
Joshua M. Carmen, Shikha Shrivastava, Zhongyan Lu, Alexander Anderson, Elaine B. Morrison, Rajeshwer S. Sankhala, Wei-Hung Chen, William C. Chang, Jessica S. Bolton, Gary R. Matyas, Nelson L. Michael, M. Gordon Joyce, Kayvon Modjarrad, Jeffrey R. Currier, Elke Bergmann-Leitner, Allison M. W. Malloy, Mangala Rao
Summary: The study demonstrates that combining a nanoparticle vaccine with a potent adjuvant enhances SARS-CoV-2-specific durable adaptive immune T cell responses.
Article
Biochemistry & Molecular Biology
Agnieszka Sulima, Fuying Li, Jeffrey Brian Morgan, Phong Truong, Joshua F. G. Antoline, Therese Oertel, Rodell C. Barrientos, Oscar B. Torres, Zoltan Beck, Gregory H. Imler, Jeffrey R. Deschamps, Gary R. Matyas, Arthur E. Jacobson, Kenner C. Rice
Summary: This study focuses on the design and synthesis of haptens for anti-heroin vaccines, evaluating their efficacy in inducing protective antibodies against heroin in vivo. The results show that haptens with a linker at the C1 position can induce protective effects, with significant differences in antibody specificity among different haptens.
Article
Immunology
Sara C. Johnston, Keersten M. Ricks, Ines Lakhal-Naouar, Alexandra Jay, Caroline Subra, Jo Lynne Raymond, Hannah A. D. King, Franco Rossi, Tamara L. Clements, David Fetterer, Samantha Tostenson, Camila Macedo Cincotta, Holly R. Hack, Caitlin Kuklis, Sandrine Soman, Jocelyn King, Kristina K. Peachman, Dohoon Kim, Wei-Hung Chen, Rajeshwer S. Sankhala, Elizabeth J. Martinez, Agnes Hajduczki, William C. Chang, Misook Choe, Paul Thomas, Caroline E. Peterson, Alexander Anderson, Isabella Swafford, Jeffrey R. Currier, Dominic Paquin-Proulx, Linda L. Jagodzinski, Gary R. Matyas, Mangala Rao, Gregory D. Gromowski, Sheila A. Peel, Lauren White, Jeffrey M. Smith, Jay W. Hooper, Nelson L. Michael, Kayvon Modjarrad, M. Gordon Joyce, Aysegul Nalca, Diane L. Bolton, Margaret L. M. Pitt
Summary: This study reported on the immunogenicity and efficacy of a protein-based COVID-19 vaccine in a monkey model, demonstrating strong immune responses and a significant reduction in lung lesions following infection.
Article
Chemistry, Multidisciplinary
Erwin G. Abucayon, Rodell C. Barrientos, Oscar B. Torres, Scott Sweeney, Connor Whalen, Gary R. Matyas
Summary: Identification and quantification of an active adjuvant and its degradation product are crucial for ensuring the safety and efficacy of drug formulations. A new LC-MS/MS method was developed to accurately quantify the active adjuvant QS-21 and its degradation product QS-21 HP in liposomal drug formulations. The method showed good specificity, sensitivity in the nanomolar range, and precise detection and quantitation for QS-21 and its degradation product.
Article
Pharmacology & Pharmacy
Erwin G. Abucayon, Mangala Rao, Gary R. Matyas, Carl R. Alving
Summary: ALFQ, a vaccine adjuvant preparation, is composed of liposomes containing saturated phospholipids, cholesterol, and two adjuvants MPLA and QS21. The addition of QS21 to nanoliposomes initiates a fusion reaction resulting in the formation of giant unilamellar vesicles (GUVs) with diameters >1.0 μm. The lipid composition analysis reveals that GUVs mainly contain cholesterol, MPLA, and QS21, suggesting that the binding of QS21 to cholesterol and the hydrophilicity of MPLA and QS21 may play important roles in the fusion process.
Article
Immunology
Nimisha Rikhi, Clara J. Sei, Mangala Rao, Richard F. Schuman, Kellie A. Kroscher, Gary R. Matyas, Kevin Muema, Camille Lange, Aba Assiaw-Dufu, Elizabeth Hussin, Ousman Jobe, Carl R. Alving, Gerald W. Fischer
Summary: An unconjugated composite peptide vaccine targeting multiple conserved influenza epitopes from hemagglutinin, neuraminidase, and matrix protein generated broad and durable immune responses in outbred mice. The vaccine recognized specific epitopes in influenza peptides and several human, avian, and swine influenza viruses.